30 Jun 2009 11:30
| For immediate release | 30 June 2009 |
MINSTER PHARMACEUTICALS PLC
("Minster" or "the Company")
Result of Annual General Meeting
Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, announces that all resolutions put to shareholders at this morning's Annual General Meeting were duly passed.
For further information:
| Minster Pharmaceuticals plc | Tel: +44 (0) 1799 506623 |
| John Russell, Chairman and Interim CEO | |
| Karl Keegan, Chief Financial Officer | Tel: +44 (0) 20 7936 9921 |
| Buchanan Communications | Tel: +44 (0) 20 7466 5000 |
| Mark Court / Rebecca Skye Dietrich / Catherine Breen | |
| Nomura Code Securities Limited | Tel: +44 (0) 20 7776 1200 |
| Chris Collins / Richard Potts |
Notes for editors:
About Minster Pharmaceuticals plc
Minster Pharmaceuticals is a drug development company focussed on neurological and psychiatric disorders. Its principal pipeline assets are tonabersat and sabcomeline. Worldwide rights to both compounds were acquired from GlaxoSmithKline and the compounds benefit from comprehensive safety tolerance data as a result of investment by GSK.
Tonabersat is the leading compound in an exciting new class of selective drugs designated as neuronal gap junction blockers. Sabcomeline, a muscarinic partial agonist, has potential in the treatment of chronic schizophrenia and the strategy for its further clinical development is currently under consideration.
Minster joined the AIM market in February 2005 and trades under the symbol MPM. For further information please visit www.minsterpharma.com.
MPM.L (MPM)